These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3704452)

  • 21. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy.
    Weinhold SL; Seeck-Hirschner M; Nowak A; Hallschmid M; Göder R; Baier PC
    Behav Brain Res; 2014 Apr; 262():8-13. PubMed ID: 24406723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluvoxamine and clomipramine in the treatment of cataplexy.
    Schachter M; Parkes JD
    J Neurol Neurosurg Psychiatry; 1980 Feb; 43(2):171-4. PubMed ID: 6766990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy.
    Coakley JH; Moorcraft J; Hipkin LJ; Smith CS; Griffiths RD; Edwards RH
    J Neurol Neurosurg Psychiatry; 1988 Dec; 51(12):1551-7. PubMed ID: 3221222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mazindol for nocturnal enuresis.
    Tiptaft RC; Woodhouse CR; Badenoch DF
    Br J Urol; 1984 Dec; 56(6):641-3. PubMed ID: 6534482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials.
    Boscolo-Berto R; Viel G; Montagnese S; Raduazzo DI; Ferrara SD; Dauvilliers Y
    Sleep Med Rev; 2012 Oct; 16(5):431-43. PubMed ID: 22055895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy.
    Baier PC; Hallschmid M; Seeck-Hirschner M; Weinhold SL; Burkert S; Diessner N; Göder R; Aldenhoff JB; Hinze-Selch D
    Sleep Med; 2011 Dec; 12(10):941-6. PubMed ID: 22036605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium oxybate in the treatment of childhood narcolepsy-cataplexy: a retrospective study.
    Mansukhani MP; Kotagal S
    Sleep Med; 2012 Jun; 13(6):606-10. PubMed ID: 22445591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multi-centre trial of mazindol ('Teronac') in general practice in Ireland.
    Evans ER; Wallace MG
    Curr Med Res Opin; 1975; 3(3):132-7. PubMed ID: 1149481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and polygraphic effects of d.1 5 HTP on narcolepsy-cataplexy.
    Autret A; Minz M; Beillevaire T; Degos C; Cathala HP
    Biomedicine; 1977 Jul; 27(5):200-3. PubMed ID: 336110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levo(-) amphetamine and dextro(+) amphetamine in the treatment of narcolepsy.
    Parkes JD; Fenton GW
    J Neurol Neurosurg Psychiatry; 1973 Dec; 36(6):1076-81. PubMed ID: 4359162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hypocretin (orexin) deficiency in narcolepsy-cataplexy].
    Nevsímalová S; Vanková J; Sonka K; Faraco J; Rogers W; Overeem S; Mignot E
    Sb Lek; 2000; 101(4):381-6. PubMed ID: 11702580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mazindol in the control of micturition.
    Woodhouse CR; Tiptaft RC
    Br J Urol; 1983 Dec; 55(6):636-8. PubMed ID: 6360295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium oxybate: new drug. Fewer attacks of cataplexy in some patients.
    Prescrire Int; 2007 Jun; 16(89):98-101. PubMed ID: 17582923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viloxazine hydrochloride in narcolepsy: a preliminary report.
    Guilleminault C; Mancuso J; Salva MA; Hayes B; Mitler M; Poirier G; Montplaisir J
    Sleep; 1986; 9(1 Pt 2):275-9. PubMed ID: 3704453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Overweight as a therapeutic problem. Experience with the appetite depressant Mazindol].
    Linke H
    Med Welt; 1976 Oct; 27(42):2021-5. PubMed ID: 792620
    [No Abstract]   [Full Text] [Related]  

  • 36. [Narcolepsy: a new perspective on diagnosis and treatment].
    Fronczek R; van der Zande WL; van Dijk JG; Overeem S; Lammers GJ
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):856-61. PubMed ID: 17472116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy/cataplexy.
    Mattarozzi K; Bellucci C; Campi C; Cipolli C; Ferri R; Franceschini C; Mazzetti M; Russo PM; Vandi S; Vignatelli L; Plazzi G
    Sleep Med; 2008 May; 9(4):425-33. PubMed ID: 17681883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite, and activity in terminal cancer patients.
    Bruera E; Carraro S; Roca E; Barugel M; Chacon R
    Cancer Treat Rep; 1986 Feb; 70(2):295-8. PubMed ID: 3512080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of clomipramine as an REM sleep suppressant in narcolepsy.
    Chen CN
    Postgrad Med J; 1980; 56 Suppl 1():86-9. PubMed ID: 7393833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AN 448 Sandoz (Mazindol) in the treatment of obesity.
    Wallace AG
    Med J Aust; 1976 Mar; 1(11):343-5. PubMed ID: 775265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.